Showing 7401-7410 of 7755 results for "".
- DermatologistOnCall Launches Online Platformhttps://practicaldermatology.com/news/20140123-dermatologistoncall_launches_online_platform/2459362/DermatologistOnCall® has launched its online platform, allowing dermatologists to efficiently diagnose and prescribe a treatment plan for patients with more routine conditions via an online portal, while reserving in-office appointments for more severe cases. After a patient registers, dermatologist
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- First Practice in Northwest Adopts ARTAS® Robotic Systemhttps://practicaldermatology.com/news/20131230-first_practice_is_northwest_adopts_artas_robotic_system/2459386/Advanced Hair Restoration of Bellevue, WA has installed the revolutionary ARTAS® Robotic System — the first and only FDA-cleared, physician-controlled, computer-assisted techno
- Acneiform Eruptions Examined in New Bookhttps://practicaldermatology.com/news/20131223-acneiform_eruptions_examined_in_new_book/2459387/A new book that addresses the differential diagnosis of acne vulgaris and treatment of acne-like condition is now available through Springer. Acneiform Eruptions in Dermatology, edited by Practical Dermatology Board Member Joshua A. Zeichner, MD, offers expert guidance on acne and syst
- Syneron's Home-Use Hair Removal Systems Receive Expanded Indicationhttps://practicaldermatology.com/news/20131219-synerons_home-use_hair_removal_systems_receive_expanded_indication/2459390/The FDA has granted Syneron Medical Ltd. and Iluminage Beauty an expanded indication for me™ brand of home-use hair removal systems. The systems, which utilize Syneron's proprietary elos technology, are now indicated for permanent reduction in hair growth. The me™ brand is owned and sold by Iluminag
- Cynosure Announces Successful Settlement of Patent Infringement Lawsuitshttps://practicaldermatology.com/news/20131217-cynosure_announces_successful_settlement_of_patent_infringement_lawsuits/2459393/Cynosure, Inc. will receive $10 million plus future royalty payments under a comprehensive settlement agreement with Tria Beauty, Inc. that ends the patent infringement litigation between Tria and Palomar Medical Technologies, which